Syarifuddin Wahid
IMMUNODEFICIENCY
CONGENEAL
(PRIMRY)
IMMUNODEFICENCY
ACQUIRED (SECONDARY)
IMMUNODEFICIENCY
CONGENETAL (PRIMARY)
IMMUNODEFICIENCY
Phagocytic Disfunction
Complement Deficiencies.
Leucocyte Adhesion Deficiency
Defect In Lymphocyte Maturation
Defect in Lymphocyte Activation
Immunodeficiency Associated with
other Inherited Diseases.
(Wiskot-Aldrich Syndrome dan
Ataxia-telangiectasia)
C3 deficiency
Classical Pathway Deficiency
Alternative Pathway Deficiency
Mannan-Binding Lectin Deficiency
Terminal Component Deficiency
Control Protein Deficincy
Complement Receptor Deficiency
Management of Complement Deficiency
IMMUNODEFICIENCY
H chain
Stem Cell
Pro-B
Pre-B
Bone Marrow
No antigen dependence
H & L chain
IgM,IgD
2. DEFECT IN
B CELL
ACTIVATION
IMMUNODEFICIENCY
TCR
No respon to antigen
Periphery
Thymus
Negative
selection
activation by
Foreign ant
2. DEFECT IN
T CELL
ACTIVATION
Immunodeficiency caused by
defects in B and T cell maturation.
Primary immunodeficiencies caused by
genetic defects in lymphocyte
maturation are shown. These defects
may affect T cell maturation alone, B
cell maturation alone, or both. The
survival of all lymphocyte progenitor
populations requires the purine salvage
pathway enzymes, ADA, and PNP. IL7R signaling (γC, IL-7Rα,
and JAK3) is required for human pro-T
cell generation. The V(D)J
recombination machinery (RAG-1,
RAG-2, and ARTEMIS) is required for
generating pre-B and pre-T cells, as is
signaling through the pre-TCR (CD45,
CD3) specifically for pre-T cells and the
pre-BCR (Igμ chain, λ5,
Igα, and BLNK) for pre-B cells.
DP, double-positive; FoB, follicular B
cells; HSC, hematopoietic stem cell;
MZB, marginal zone B cells.
Downloaded from: StudentConsult (on 20 November 2007 07:29 AM)
2005 Elsevier
Severe Combined
Immunodeficiency (SCID)
- Common Chain Receptor deficiency.
(X-Linked SCID)
- Adenosine Deaminase (ADA) deficiency
- RAG-1 or RAG-2 deficiency
Stem Cell
Pro-B
ADA, PNPdeficiency
(Autosomal SCID)
Pre-B
TCR
DNA synthesis
Autosomal resessive
of inheritance
Adenosine Deaminase
(ADA) deficiency
Accumulation of
S-adenosylhomocysteine
& deoxyadenosine
tripohosphate(dATP)
Accumulation of
deoxyguanosine &
deoxyguanosine
Triphosphate (dGTP)
No mature Lymphocytes
No help factors
No differentiation of B cell to
antibody-producing plasma cells
HISTORY
1953 BRUTON OBSERVED 8 YEARS
BOY WHO HAD SEPSIS AND ARTHRITIS
SINCE AGE 4 YEARS
NO RESPONSE TO THYPOID AND
DIFTERI IMUNIZATION
SERUM PROTEIN NO GAMMA
GLOBULIN
BRUTON DISEASE:
NO B CELLS IN THE BLOOD AND LYMPHOID
TISSUE
X LINKED AGAMMAGLOBULINAEMIA AFFECTING
MALES
LYMPH NODES VERY SMALL.
THEIR SERUM CONTAINS NO IgA, IgM, IgD OR
IgE. IgG ONLY SMALL AMOUNT
IN THE 6-12 MONTHS PROTECTED FROM
INFECTION BY MATERNAL IgG
AFTER MATERNAL IgG EXHAUSTED
RECURRENT PYOGENIC INFECTION.
INFUSED I.V. LARGE DOSES OF GAMMA
GLOBULIN REMAIN HEALTHY
X-LINKED AGAMMAGLOBULINEMIA
IgM,IgD
Pro-B
Pre-B
Bone Marrow
Agammaglobulinemia
Deficient T Cell
Maturation
Abnormal in Calcium
homeostatis and tetany.
IMMUNODEFICIENCY
TCR
No respon to antigen
Periphery
Thymus
Negative
selection
activation by
Foreign ant
Congenetal malformation
DiGEORGES SYNDROME
T CELL DEFICIENCY
THYMUS AND PARATHYROID NOT DEVELOP
LOST CELLULAR IMMUNITY
EASY INFECTION BY FUNGUS AND VIRUS
TETANY
T CELL DEFICIENCY VARIABLE HOW
BADLY THE THYMUS GLAND IS AFFECTED
Abnormal in
T Cell help
Immnoglobulin
Mature B Cell
Plasma Cell
Cause : ?
Symptoms :
- Absent of plasma cells in lymphoid tissue
- Hypogammaglobulinemia
(immunoglobulin deficiency)
Nucleous
T cells
activation
membrane cells
CD40L
TCR
cytokines
MHC
cytokine
receptors
Ag
1
CD40
membrane cells
3
No heavy chain
isotype switching
helper effect
B cells
2
Nucleous
CD22 ICAM-1(CD54)
LFA3
B7
CD72
DEFECT IN
T CELL
ACTIVATION
APC
CLASS II MHC
Accessory Molecules
ANTIGEN
CD4
(Coreceptor)
INF
IL-2
..
CD5
CD28 CD2
CD45 LFA-1 Zap-70
TCR
TCR-CD3
COMPLEX
CD3
HELPER
CD3
T CELL
Endoplasmic Reticulum
Peptide-MHC Bound
TAP
Presentation
ER
MHC-I
CTL(CD8)
TCR
NUCLEOTED CELLS
Defect in
Class-I MHC
Expression
Peptide-MHC Bound
Phagocytosis
Presentation
Mature
CD4
TCR
Antigen
ER
MHC-II
Thymic APC/
Epithelial Cell
Mutation of Tanscription
factor RFX5 or CIITA
Defect in Class-II
MHC expression
No positive Selection
in the thymus
Positive
selection
Thymic
epithelial cell
Thymic
epithelial cell
MHC-II
Negative
selection
Thymic
APC
MHC-II
MHC-II
TCR
TCR
CD4 CD8
(low affinity)
CD4 CD8
(high affinity)
TCR
CD4
CD8
Apoptosis
Survive
Apoptosis
WISKOTT-ALDRICH SYNDOME
(WAS)
THE CAUSE mutasi pada gen yang
mengkode pembentukan protein ( WAS
Protein) yang akan mengikat berbagai
molekul adaptor dan komponen
sitoskeletal dalam sel hematopoietik
sehingga trombosit dan neutropil kecil,
tidak berkembang normal dan gagal
bermigarsi
WISKOTT-ALDRICH SYNDOME
(WAS)
LOW THROMBOCYT THROMBOCYTOPENIA
AFFECTED MALES (X-linked disease)
DEVELOP SEVERE ECZEMA AS WELL AS
PYOGENIC AND OPPORTUNISTIC
INFECTIONS.
IN THE SERUM IgA AND Ig E INCREASED, IgG
NORMAL, IgM DECREASED
T CELLS DEFECTED IN FUNCTION.
ACQUIRED IMMUNODEFICIENCY
MALNUTRITION
NEOPLASMA
INFECTIONS
SPLEENECTOMY
CHEMOTHERAPOITIC DRUGS.
ANTI-INFLAMATORY &
IMMUNOSUPRESSIVE DRUGS.
MALNUTRITION
IMMUNODEFICIENCY
NEOPLASMS
Bone marrow tumors,
metastatic to marrow
and leucemia
Product of Tumor
Cells (TGF-)
Hodgkin Disease
Impairment in
T Cell function
INFECTIOUS
HIV
HTLV-1
CD-4 T CELL
KILLING
AIDS
M-TBC/FUNGI.
ANERGY
LYMPHOTROPIC
ATL
MALARIA
DEPRESSED
T CELL
FUNCTION
HIV INFECTION
CLINICAL LATENCY
Figure 20-3 Structure of HIV-1. An HIV-1 virion is shown next to a T cell surface. HIV-1 consists of two identical strands of RNA (the viral genome) and associated
enzymes, including reverse transcriptase, integrase, and protease, packaged in a cone-shaped core composed of p24 capsid protein with a surrounding p17 protein
matrix, all surrounded by a phospholipid membrane envelope derived from the host cell. Virally encoded membrane proteins (gp41 and gp120) are bound to the
envelope. CD4 and chemokine receptors on the host cell surface function as HIV-1 receptors. (© 2000 Terese Winslow.)
Figure 20-5 HIV life cycle. The sequential steps in the life cycle of HIV are shown, from initial infection of a host cell to viral replication and release of a new virion. For the
sake of clarity, the production and release of only one new virion are shown. An infected cell actually produces many virions, each capable of infecting cells, thereby
amplifying the infectious cycle.
Figure 20-8 Clinical course of HIV disease. A. Plasma viremia, blood CD4+ T cell counts, and clinical
stages of disease. About 12 weeks after infection, blood-borne virus (plasma viremia) is reduced to very
low levels (detectable only by sensitive reverse-transcriptase polymerase chain reaction assays) and
stays this way for many years. Nonetheless, CD4+ T cell counts steadily decline during this clinical
latency period because of active viral replication and T cell infection in lymph nodes. When CD4+ T cell
counts drop below a critical level (about 200/mm3), the risk for infection and other clinical components of
AIDS is high. B. Immune response to HIV infection. A CTL response to HIV is detectable by 2 to 3
weeks after the initial infection and peaks by 9 to 12 weeks. Marked expansion of virus-specific CD82+ T
cells occurs during this time, and up to 10% of a patient's CTLs may be HIV specific at 12 weeks. The
humoral immune response to HIV peaks at about 12 weeks.
Infection
Kaposis Sarcoma
Other Cancer
Lymphadenopathy
Syndrome
Figure 20-6 Mechanism of HIV entry into a cell. In the model depicted, sequential conformational changes in gp120 and gp41 are induced by binding to CD4. These
changes promote binding of the virus to the coreceptor (a chemokine receptor) and fusion of the HIV-1 and host cell membranes. The fusion peptide of activated gp41
contains hydrophobic amino acid residues that mediate insertion into the host cell plasma membrane.
HIV VIRION
CLINICAL SYMPTOMS
EXTENSIVE VIRUS REPLICATION